Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

APC-APN-306

15 evidence topics · 4 sources

Objective
Location and study date
Registry dates and status, last updated May 2025
FieldRegistry entry
Study start (actual)“2024-07-03”
Primary completion (estimated)“2026-06-30”
Last update posted“2025-05-13”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
FieldRegistry entry
Enrollment (estimated)“1280”
Description of analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design: open-label, single-group continuation study with no comparator; the registered primary outcomes are counts of participants with adverse events, vital sign abnormalities, and concomitant therapy.
  • Population: eligibility required completion of a parent phase 3 trial without permanent discontinuation of study drug, so participants who stopped study drug in the parent trials were not eligible.
  • Status: the registry record (last updated 2025-05-13) lists an estimated enrollment of 1,280 and an estimated primary completion of 2026-06-30, while the prospectus states the trial was completed in 2026.
  • Results: the only results are interim data from a 2025 congress abstract, with 102 participants enrolled (70% of eligible). The abstract states that data collected to date support long-term safety without reporting adverse event data, and no baseline, efficacy, patient-reported outcome, or analysis-set information is available.
  • Exploratory ring oximetry and mobile-application PROs were optional; 73 participants (72%) opted in.
  • Sponsor: the prospectus states that Syneos provided services to the company in connection with the trial.